These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18431556)

  • 1. [Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer].
    Dietel M; Tannapfel A; Baretton G; Kreipe H; Kloor M; Gabbert H; Kirchner T
    Chirurg; 2008 Jun; 79(6):576-9. PubMed ID: 18431556
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology].
    Tannapfel A
    Pathologe; 2008 Feb; 29(1):93-6. PubMed ID: 18210112
    [No Abstract]   [Full Text] [Related]  

  • 3. Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer.
    Zikria J; Krishnamoorthy S; Kaley K; Saif MW
    Int J Colorectal Dis; 2011 Oct; 26(10):1353-4. PubMed ID: 21229361
    [No Abstract]   [Full Text] [Related]  

  • 4. Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status.
    Elez E; Alsina M; Tabernero J
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S15-6. PubMed ID: 20189055
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.
    Monzon FA; Ogino S; Hammond ME; Halling KC; Bloom KJ; Nikiforova MN
    Arch Pathol Lab Med; 2009 Oct; 133(10):1600-6. PubMed ID: 19792050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
    J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
    Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
    Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
    [No Abstract]   [Full Text] [Related]  

  • 14. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
    Weber J; McCormack PL
    BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
    Katsios C; Ziogas DE; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer: Pinprick diagnostics.
    Vilar E; Tabernero J
    Nature; 2012 Jun; 486(7404):482-3. PubMed ID: 22739312
    [No Abstract]   [Full Text] [Related]  

  • 20. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.